LOS ANGELES, June 14, 2004 (PRIMEZONE) -- Bio-Life Labs, Inc. (OTCBB:BLFE) announced today that the company has launched its corporate website at: www.biolifelabs.com.
The website was developed to provide the company's investors, partners, vendors and other interested parties with the most accurate and timely information regarding Bio-Life Labs, Inc. The website features an investor section with information on the Company's SEC filings, press releases, historical stock prices and requests for information. Interested parties may register at the website to receive updates when the company disseminates information to the public.
"Our new corporate website was designed to communicate the Company's message clearly and accurately to all interested parties," said Bio-Life Labs' President and CEO Nancy LeMay. "We have paid special attention to our share owners, as well as those interested in finding out more about Bio-Life Labs, Inc. As a Company, we are committed to transparency and proper corporate governance, striving to be ahead of the curve on issues of compliance and disclosure. We hope that our website will help Bio-Life Labs, Inc. maintain an open line of communication with the public."
About Bio-Life
Bio-Life, Labs, Inc. is a research-driven biotechnology company focused on discovery, development, manufacturing, and commercialization of breakthrough treatments for Cancer, Diabetes Mellitus, and Hepatitis C. Our first product candidate Carcinoderm(tm) is a topical treatment that we have formulated to destroy skin cancer cells in patients diagnosed with Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma in a one-time application without harming surrounding healthy tissue.
Bio-Life labs, Inc. cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Bio-Life labs, Inc. that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Bio-Life labs, Inc.'s business including, without limitation, statements about: difficulties or delays in research, development, testing, obtaining regulatory approval, producing and marketing its technologies and products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; its ability to meet product development objectives; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to attract and retain experienced scientists and management; as well as other risks detailed in Bio-Life labs, Inc.'s Securities and Exchange Commission filings. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Bio-Life labs, Inc. undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.